替代终点:临床流行病学中的一个关键概念
替代终点是作为临床结局替代指标的生物标志物或中间结局,常用于加速研究或决策,而患者重要结局是患者直接相关和重视的健康结局。替代终点与被替代的患者重要结局之间需有科学依据充分理解的关系,且替代终点的变化应能一致且可预测地反映患者重要结局的变化。替代终点应显示阈值效应,即干预引起的特定变化与可预测的患者重要结局变化相关,这有助于建立有意义的cutoff或治疗效应目标。尽管替代终点在某些情况下有优势,但其使用需要仔细验证以确保可靠预测真实临床结局,其有效性应由稳健的科学证据和严格评估支持后方可考虑并标记为替代终点。
要点
- 替代终点是生物标志物或中间结局,用于替代临床结局以加速研究或决策。
- 患者重要结局是患者直接相关和重视的健康结局。
- 替代终点需科学验证其能可靠预测真实临床结局,并显示阈值效应。
核心结论
- 替代终点的使用需要仔细验证以确保可靠预测真实临床结局,其有效性应由稳健的科学证据和严格评估支持后方可考虑并标记为替代终点。
研究设计与样本
- 本文为概念阐述性文章,旨在详细说明替代终点的使用和理解。
主要发现
- 替代终点是作为临床结局替代指标的生物标志物或中间结局,常用于加速研究或决策。
- 患者重要结局是患者直接相关和重视的健康结局,临床试验可能测量了干预对其他终点的影响,这些终点与患者主要重要结局相关但不同。
- 替代终点与被替代的患者重要结局之间应有科学依据充分理解的关系,且生物学上合理认为替代终点的变化将一致且可预测地反映患者重要结局的变化。
- 替代终点应显示阈值效应,即干预引起的特定变化与可预测的患者重要结局变化相关,这有助于建立有意义的cutoff或治疗效应目标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surrogate endpoints are biomarkers or intermediate outcomes that are used as substitutes for clinical outcomes of interest, often to expedite research or decision-making. In contrast, patient-important (or patient-centered) outcomes are health outcomes that are of direct relevance and importance to patients themselves; clinical trials may have measured the impact of the intervention on other endpoints related to, but different from, those of primary importance to patients. This article aims to elaborate on the use and understanding of surrogate endpoints. There should be a well-understood and scientifically grounded relationship between the surrogate (replacement) and the patient-important (target) endpoint it is intended to represent. It should be biologically plausible that changes in the surrogate will consistently and predictably reflect changes in the patient-important endpoint. The surrogate endpoint should show a threshold effect, meaning that a specific change (or state) in the surrogate with an intervention (relative to the comparator) is associated with a predictable (change in the) patient-important outcome. This helps establish a meaningful cutoff or target for the treatment effect on the surrogate endpoint. While surrogate endpoints offer advantages in certain situations, it is important to remember that their use requires careful validation to ensure they reliably predict the true clinical outcome. The validity of "surrogate endpoints" should be supported by robust scientific evidence and rigorous evaluation before these can be considered and labeled as surrogate endpoints.
引用
- Christensen R, Ciani O, Manyara AM, et al. Surrogate endpoints: a key concept in clinical epidemiology. J Clin Epidemiol. 2023. PMID: 38142762. doi:10.1016/j.jclinepi.2023.111242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。